Overview

Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction

Status:
Completed

Trial end date:
2005-02-01

Target enrollment:
0

Participant gender:
All

Summary

COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible provided they were thought to have ST elevation or other ischaemic ECG abnormality with no clear indication for, or contraindication to, trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death. (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol versus placebo.) The two main study endpoints are death and the composite outcome of death, non-fatal reinfarction or stroke during the scheduled treatment period in hospital.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of Oxford

Collaborators:

AstraZeneca
Sanofi

Treatments:

Clopidogrel
Metoprolol
Ticlopidine

Criteria

Inclusion Criteria:

- Patients presenting with ST elevation, left bundle branch block or ST depression
within 24 hours of the onset of the symptoms of suspected acute MI

Exclusion Criteria:

- clear indications for, or contraindications to, any of the study treatments